Skip to content

Treatment of Corneal Wounds Emergencies During the COVID-19 Shutdown: Absorbable 10-0 Vicryl Sutures as a Valuable Strategy.

Treatment of Corneal Wounds Emergencies During the COVID-19 Shutdown: Absorbable 10-0 Vicryl Sutures as a Valuable Strategy.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04733846
Enrollment
10
Registered
2021-02-02
Start date
2020-03-18
Completion date
2021-12-05
Last updated
2022-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Trauma

Keywords

Corneal, penetrating injury, lamellar laceration, COVID, polyglactin, Vicryl

Brief summary

Vicryl (polyglactin) 10-0 resorbable suture is rarely used, little known to ophthalmologists but may offer therapeutic and practical advantages in eligible cases of corneal trauma, particularly during a COVID-19 pandemic. This has imposed new sanitary restrictions : limited access to the operating room in ophthalmology only for functional emergencies and a drastically reduced capacity for external consultations in favor of teleconsultation. The aim of this study is to evaluate the Vicryl 10-0 (polyglactin 910) resorbable monofilament suture in corneal trauma, rather than classic Nylon 10-0: structural and functional results, and adaptation of postoperative follow-up during a sanitary crisis period.

Interventions

OTHERdata collection

Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma

Sponsors

Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Corneal penetrating injury and/or lamellar laceration

Exclusion criteria

* Corneal Penetrating injury trauma requiring necessarily ONLY Nylon 10-0 * Traumatism requiring necessarily a cryopreserved human amniotic membrane (for example) * Traumatism eligible for biological glue (long-axis wound \< 2 mm)

Design outcomes

Primary

MeasureTime frameDescription
change visual acuity (Snellen scale) from baseline and 2, 6, 12 and 18 months after the interventionMonths: 0, 2, 6, 12, 18Collected in the medical record.
change Visual acuity (Parinaud scale) from baseline and 2, 6, 12 and 18 months after the interventionMonths: 0, 2, 6, 12, 18Collected in the medical record.

Secondary

MeasureTime frameDescription
Astigmatism (diopter)Months: 0, 2, 6, 12, 18Collected in the medical record. Measured by OCT-TOMEY-CASIA).
Number of postoperative external consultationsMonths: 0, 2, 6, 12, 18Collected in the medical record.
Adverse eventsMonths: 0, 2, 6, 12, 18Collected in the medical record. All adverse events connecting to the eye surgery.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026